RCT | Efficacy of a targeted-release formulation of budesonide for treating primary immunoglobulin A nephropathy.

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy – Kidney International

Commentary: Oral Steroid Safely Treats IgA Nephropathy: Trial Published – Medscape (free registration required)

Commentary on Twitter (thread – click for more)

Published! (Months after being FDA approved) by @IgAN_JBarratt et al

The phase 3A part of targeted release budesonide (called Nefecon) in IgA https://t.co/weF2dZ2Efg

They included IgA with proteinuria > 1g and GFR 35 to 90 + max supported RASi

see how that worked out:

1/ pic.twitter.com/OK2cvElQvO

— Swapnil Hiremath, MD (@hswapnil) October 19, 2022